Marco Davila, MD, PhD, discusses how a study of tumor drivers of CAR T-cell therapy resistance in LBCL may promote future biomarker investigations.
Marco Davila, MD, PhD
Advertisement
Marco Davila, MD, PhD, the senior vice president and associate director for Translational Research in the Department of Medicine, as well as the Rustum Family Endowed Chair in Translational Research at Roswell Park Comprehensive Cancer Center
Articles by Marco Davila, MD, PhD
Marco Davila, MD, PhD, discusses research investigating ways to combat immune escape mechanisms in LBCL treated with CD19-directed CAR T-cell therapy.
Marco Davila, MD, PhD, discusses emerging strategies to overcome resistance to CD19-directed CAR T-cell therapy in aggressive large B-cell lymphoma.
Marco Davila, MD, PhD, explains the role of intrinsic tumor drivers in CD19 CAR T-cell therapy resistance in aggressive large B-cell lymphoma.
Marco Davila, MD, PhD, discusses how to shape the future of medicine with gene and cell therapy.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5